Exelixis, Inc.

LSE:0IJO Stock Report

Market Cap: US$10.3b

Exelixis Valuation

Is 0IJO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0IJO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0IJO ($35.69) is trading below our estimate of fair value ($135.7)

Significantly Below Fair Value: 0IJO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0IJO?

Key metric: As 0IJO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0IJO. This is calculated by dividing 0IJO's market cap by their current earnings.
What is 0IJO's PE Ratio?
PE Ratio22x
EarningsUS$466.92m
Market CapUS$10.26b

Price to Earnings Ratio vs Peers

How does 0IJO's PE Ratio compare to its peers?

The above table shows the PE ratio for 0IJO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51x
GNS Genus
141.4x37.7%UK£1.1b
BVXP Bioventix
24.3xn/aUK£197.0m
HIK Hikma Pharmaceuticals
19.3x12.7%UK£4.3b
300122 Chongqing Zhifei Biological Products
18.8x43.1%CN¥70.5b
0IJO Exelixis
22x15.6%US$10.3b

Price-To-Earnings vs Peers: 0IJO is good value based on its Price-To-Earnings Ratio (22x) compared to the peer average (51x).

Price to Earnings Ratio vs Industry

How does 0IJO's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0IJO 22.0xIndustry Avg. 26.5xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0IJO is good value based on its Price-To-Earnings Ratio (22x) compared to the European Biotechs industry average (26.5x).

Price to Earnings Ratio vs Fair Ratio

What is 0IJO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0IJO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22x
Fair PE Ratio27.7x

Price-To-Earnings vs Fair Ratio: 0IJO is good value based on its Price-To-Earnings Ratio (22x) compared to the estimated Fair Price-To-Earnings Ratio (27.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0IJO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$35.69
US$31.83
-10.8%
15.7%US$38.00US$18.90n/a22
Nov ’25US$34.07
US$31.83
-6.6%
15.7%US$38.00US$18.90n/a22
Oct ’25US$26.05
US$27.60
+6.0%
14.2%US$34.36US$18.00n/a22
Sep ’25US$26.00
US$27.38
+5.3%
14.6%US$35.07US$18.00n/a21
Aug ’25US$24.18
US$26.59
+10.0%
15.7%US$35.07US$17.00n/a22
Jul ’25US$22.41
US$26.59
+18.7%
15.7%US$35.07US$17.00n/a22
Jun ’25US$21.54
US$26.59
+23.4%
15.7%US$35.07US$17.00n/a22
May ’25US$21.37
US$26.76
+25.2%
15.3%US$35.07US$17.00n/a22
Apr ’25US$23.77
US$26.63
+12.0%
14.6%US$32.35US$18.00n/a21
Mar ’25US$22.61
US$26.63
+17.8%
14.6%US$32.35US$18.00n/a21
Feb ’25US$21.78
US$26.52
+21.7%
14.2%US$32.00US$18.00n/a21
Jan ’25US$24.05
US$26.44
+10.0%
15.2%US$32.00US$18.00n/a21
Dec ’24US$21.86
US$25.75
+17.8%
16.2%US$32.00US$18.00n/a19
Nov ’24US$21.00
US$25.68
+22.3%
16.3%US$32.00US$18.00US$34.0719
Oct ’24US$22.04
US$25.58
+16.0%
16.3%US$32.00US$18.00US$26.0519
Sep ’24US$22.70
US$25.00
+10.1%
17.2%US$32.00US$18.00US$26.0018
Aug ’24US$19.67
US$24.90
+26.6%
16.9%US$32.00US$17.00US$24.1817
Jul ’24US$19.02
US$25.31
+33.1%
16.6%US$32.00US$17.00US$22.4117
Jun ’24US$19.55
US$25.32
+29.5%
16.6%US$32.00US$17.00US$21.5417
May ’24US$18.40
US$25.02
+36.0%
16.9%US$32.00US$17.00US$21.3717
Apr ’24US$19.03
US$24.97
+31.2%
16.8%US$32.00US$17.00US$23.7718
Mar ’24US$17.41
US$25.25
+45.0%
17.1%US$32.00US$17.00US$22.6118
Feb ’24US$17.27
US$25.05
+45.1%
16.8%US$32.00US$17.00US$21.7817
Jan ’24US$15.76
US$25.62
+62.6%
16.4%US$32.00US$18.00US$24.0516
Dec ’23US$17.09
US$26.06
+52.5%
17.6%US$35.00US$18.00US$21.8616
Nov ’23US$16.88
US$26.87
+59.2%
16.0%US$35.00US$18.00US$21.0016

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Formycon

€857.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

7D

3.6%

1Y

-24.5%

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€64.00

7D

3.6%

1Y

15.7%

hVIVO

UK£144.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-3.8%

1Y

4.9%